bpc-157 human clinical trial dosing protocol BPC-157 Dosing (Common Protocols) πΉ Oral / Subcutaneous β’ 500 mcg daily β’ Duration: 6 weeks πΉ Intramuscular / Peritendinous β’ 1 mg daily β’ Duration: 6 weeks β οΈ Note: Not approved BPC-157 (5mg Vial) Dosage Protocol
Description
Not for human consumption, medical use, or therapeutic applications
Supported by numerous randomized controlled trials for knee osteoarthritis, tennis elbow, Achilles tendinopathy, and more
Chronic conditions may show slower progression
WHAT ARE TREATMENTS LIKE
However, dramatic changes in body composition within 30 days from lipotropic injections alone are uncommon
This 20mg total Blend provides the experimental consistency needed for extended studies, verified at 99% purity via Janoshik COAs
